EGFR (Ab-869) Antibody

What is the EGFR (Ab-869) Antibody and what epitope does it recognize?

EGFR (Ab-869) Antibody is a rabbit polyclonal antibody that recognizes the endogenous level of total EGFR protein. The antibody is generated using a synthetic peptide sequence around amino acids 867-871 (K-E-Y-H-A) derived from Human EGFR. This region is highly conserved, making the antibody cross-reactive with human, mouse, and rat EGFR proteins . The antibody binds to a region near the C-terminus of the EGFR protein and recognizes EGFR regardless of its phosphorylation status . This makes it particularly useful for detecting total EGFR levels in experimental systems where phosphorylation states may vary.

What are the recommended applications and working dilutions for EGFR (Ab-869) Antibody?

The EGFR (Ab-869) Antibody has been validated for several experimental applications:

For western blotting, optimal results are achieved using PVDF membranes blocked with 5% low-fat milk diluted in TTBS. Both primary and secondary antibodies should be diluted in 5% low-fat milk in TTBS .

What are the proper storage and handling protocols for EGFR (Ab-869) Antibody?

EGFR (Ab-869) Antibody is supplied at a concentration of 1.0 mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol . For optimal preservation of antibody activity, the following storage conditions are recommended:

• Short-term storage (up to 6 months): 4°C

• Long-term preservation: -20°C

To maintain antibody integrity, avoid repeated freeze-thaw cycles as this can lead to protein denaturation and loss of binding activity. If frequent use is anticipated, consider aliquoting the antibody into smaller volumes before freezing .

How can I validate the specificity of EGFR (Ab-869) Antibody in my experimental system?

Validating antibody specificity is crucial for ensuring reliable research outcomes. For EGFR (Ab-869) Antibody, consider implementing the following validation strategies:

• Positive and negative controls: Use cell lines with known EGFR expression levels. A549 cells serve as a reliable positive control, while MCF-7 cells can be used as a negative control for western blotting applications .

• Expected band size verification: The antibody should detect a specific band at approximately 175 kDa in western blot applications when using appropriate positive controls .

• Blocking peptide competition: Pre-incubate the antibody with its immunizing peptide before application to demonstrate binding specificity.

• Knockdown validation: Compare antibody staining/binding between wild-type samples and those with EGFR knockdown (siRNA or CRISPR).

• Cross-method validation: Confirm EGFR detection across multiple methods (e.g., WB, IHC, IP) to ensure consistent results.

This comprehensive validation approach aligns with recommendations from studies examining reproducibility challenges in cancer biology research .

What factors contribute to inconsistent results when using EGFR antibodies in cancer research?

Research reproducibility with antibodies like EGFR (Ab-869) can be challenged by several factors:

• Protocol variations: Even minor modifications to experimental protocols can significantly impact results. In the Reproducibility Project: Cancer Biology, researchers found that 71% of attempted experiments required protocol modifications ranging from minor to extreme .

• Antibody batch variation: Different lots of the same antibody may have subtle variations in specificity and sensitivity.

• Sample preparation differences: Variations in sample preparation, including fixation methods for IHC and lysis conditions for WB, can affect epitope accessibility.

• Insufficient reporting of methods: The Reproducibility Project found that many original papers fail to report key methodological details, with 27% of experiments presenting only representative images and 21% not specifying which statistical tests were conducted .

• Cellular context differences: EGFR expression, localization, and post-translational modifications vary across cell types and experimental conditions.

To improve consistency, researchers should thoroughly document methodological details, including antibody concentration, incubation conditions, blocking reagents, and detection methods .

How does EGFR (Ab-869) Antibody binding compare with pH-dependent anti-EGFR antibodies for tumor-selective targeting?

EGFR (Ab-869) Antibody recognizes EGFR regardless of pH conditions, binding to the receptor in both normal and tumor tissues. This differs fundamentally from newly developed pH-dependent anti-EGFR antibodies, which exploit the acidity of the tumor microenvironment for selective binding.

Recent research has developed pH-dependent antibodies (like G532) that bind strongly to EGFR under acidic conditions (pH 6.5) but weakly under neutral conditions (pH 7.4) . This pH-dependency provides several advantages in cancer research and potential therapeutic applications:

For research focusing specifically on tumor-selective targeting or investigating the role of the tumor microenvironment in EGFR signaling, pH-dependent antibodies might offer advantages over standard antibodies like EGFR (Ab-869) .

What strategies can optimize western blot protocols using EGFR (Ab-869) Antibody?

Optimizing western blot protocols for EGFR (Ab-869) Antibody requires attention to several critical parameters:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors to prevent EGFR degradation

  • Standardize protein loading (40 μg of lysate recommended)

  • Denature samples at 90°C for 5 minutes in appropriate sample buffer

• Gel electrophoresis and transfer:

  • Use 4-12% Bis-Tris gels for optimal resolution of the 175 kDa EGFR protein

  • Run at approximately 160 volts for 1 hour

  • Transfer to PVDF membranes for optimal antibody binding

• Blocking and antibody incubation:

  • Block with 5% low-fat milk in TTBS

  • Dilute antibodies in the same blocking solution

  • Initial recommended dilution: 1:500-1:1000, optimizable up to 1:10,000 depending on EGFR abundance

• Detection system optimization:

  • Secondary antibody selection should match the detection method (HRP, fluorescent, etc.)

  • For infrared detection systems, IRDye 680LT Goat Anti-Rabbit at 1:10,000 dilution has been validated

• Controls:

  • Include positive control (A549 cells) and negative control (MCF-7 cells)

  • Consider including a molecular weight marker to confirm band size (~175 kDa)

Following these optimized protocols can help ensure consistent and specific detection of EGFR in western blot applications.

How should researchers design experimental controls when investigating EGFR signaling using the Ab-869 antibody?

Designing robust controls for EGFR signaling studies using Ab-869 antibody requires a multi-layered approach:

• Expression level controls:

  • Positive control: Use cell lines with confirmed high EGFR expression (A549, A431, keratinocytes in normal epidermis, or placenta)

  • Negative control: Include cell lines with low/no EGFR expression (MCF-7)

  • Gradient controls: Consider including cell lines with intermediate expression levels to establish a dynamic range

• Antibody specificity controls:

  • Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

  • Isotype control: Include matched concentration of non-specific rabbit IgG to identify non-specific binding

  • Secondary-only control: Omit primary antibody to assess secondary antibody background

• Functional controls for EGFR signaling studies:

  • EGF stimulation: Include samples with/without EGF treatment to demonstrate receptor activation

  • EGFR inhibition: Include samples treated with EGFR tyrosine kinase inhibitors (TKIs) or targeted silencing

  • Pathway component controls: Assess downstream signaling elements (ERK1/2, AKT, STAT3) to confirm pathway activation/inhibition

• Reproducibility controls:

  • Technical replicates: Minimum of three per experimental condition

  • Biological replicates: Independent experiments from different cell passages or animal subjects

  • Cross-methodology validation: Confirm key findings using alternative detection methods

Incorporating these controls addresses common challenges in reproducibility identified in cancer biology research and helps ensure reliable interpretation of EGFR signaling data .

How do post-translational modifications affect EGFR detection with Ab-869 antibody?

The EGFR protein undergoes numerous post-translational modifications that can potentially impact antibody binding and experimental interpretation:

When designing experiments, researchers should consider how these modifications might affect their specific experimental questions and interpretation of results with the Ab-869 antibody.

What approaches help troubleshoot inconsistent results between immunoblotting and immunohistochemistry using EGFR (Ab-869) Antibody?

Discrepancies between western blot (WB) and immunohistochemistry (IHC) results are common challenges when using antibodies like EGFR (Ab-869). The following systematic troubleshooting approach can help reconcile inconsistent findings:

• Identify potential sources of variation:

  Parameter	Western Blot	Immunohistochemistry
  Sample preparation	Denatured proteins	Fixed, potentially cross-linked proteins
  Epitope accessibility	High (denatured state)	May be limited by fixation/processing
  Background sources	Non-specific protein binding	Endogenous peroxidases, biotin, etc.
  Recommended dilution	1:500-1:1000	1:50-1:100
  Quantification	Semi-quantitative	Typically qualitative

• Methodological adjustments:

  • For IHC: Test multiple antigen retrieval methods (heat-induced vs. enzymatic)

  • For WB: Try native vs. denatured conditions if conformational epitopes are suspected

  • Standardize fixation time for IHC specimens

  • Optimize blocking conditions for both methods

• Cross-validation approaches:

  • Perform immunofluorescence to bridge between techniques

  • Use multiple antibodies targeting different EGFR epitopes

  • Combine with mRNA expression analysis (qPCR, RNA-seq)

  • Include siRNA knockdown controls in both methods

• Biological context considerations:

  • Cell-type specific expression patterns may explain tissue-level differences

  • Heterogeneous expression within tissues may not be reflected in whole-tissue lysates

  • Consider subcellular localization differences (membrane vs. cytoplasmic)

The Reproducibility Project: Cancer Biology found that protocol modifications were needed in 71% of experiments, with the extent of modifications varying widely . This highlights the importance of systematic optimization when translating methods across experimental platforms.

How can EGFR (Ab-869) Antibody be used to study resistance mechanisms to EGFR-targeted therapies?

EGFR (Ab-869) Antibody can play an important role in investigating resistance mechanisms to EGFR-targeted therapies through several methodological approaches:

• Monitoring receptor dynamics:

  • Track changes in total EGFR levels before, during, and after treatment with TKIs or therapeutic antibodies

  • Compare EGFR expression between sensitive and resistant cell populations

  • Assess EGFR levels in patient-derived xenograft models during treatment response and progression

• Investigating bypass pathway activation:

  • Use EGFR (Ab-869) in multiplexed immunoblotting to simultaneously detect EGFR and other RTKs implicated in resistance (MET, AXL, IGF1R)

  • Research has shown that combination treatments with TKIs and antibodies can cause trans-downregulation of multiple RTKs, potentially preventing resistance

  • Compare expression patterns between parental and resistant cell lines

• Studying EGFR mutations and variants:

  • Combine Ab-869 (total EGFR) with mutation-specific antibodies to track the emergence of resistant clones (e.g., T790M mutation)

  • Investigate expression of EGFR splice variants in resistant populations

  • Common resistance mechanisms include secondary EGFR mutations (T790M), overexpression of AXL, and amplification of MET or HER2

• Evaluating combination therapy effects:

  • Assess how EGFR levels change during combination treatments

  • Research indicates that upfront admixing of antibodies and EGFR inhibitors can prevent emergence of resistance compared to sequential therapy

  • Study whether treatment duration and TKI specificity affect EGFR expression patterns

This antibody serves as a valuable tool for understanding the complex evolving tumor cell resistance mechanisms against EGFR-targeted therapies, including those involving exosomes, non-coding RNA, and the tumor microenvironment .

What considerations are important when using EGFR (Ab-869) Antibody for reproducible cancer biology research?

The Reproducibility Project: Cancer Biology identified several challenges that researchers should address when using antibodies like EGFR (Ab-869) for cancer research:

• Complete protocol documentation:

  • Document all experimental details including antibody concentration, incubation times/temperatures, and detection methods

  • The project found that none of the 193 experiments they attempted to replicate were described completely enough to design a replication protocol without requesting clarifying details

• Statistical reporting and data sharing:

  • Report key descriptive and inferential statistics (27% of experiments in the project only presented representative images)

  • Share raw data when possible (raw data was publicly accessible for only 2% of experiments in the project)

  • Include all necessary statistical information (21% of experiments reporting inferential test outcomes did not report which test was conducted)

• Validation across systems:

  • Validate antibody performance across different experimental systems

  • The project found that even with original materials and peer-reviewed protocols, implementation challenges were common

  • Consider that observed results may depend on methodological factors not identified by original authors

• Protocol modifications and transparency:

  • Document any modifications needed to established protocols

  • The project found that 71% of experiments required modifications ranging from minor to extreme

  • Be transparent about challenges encountered during implementation

By addressing these considerations, researchers can improve the reproducibility and reliability of cancer biology research using EGFR (Ab-869) Antibody, contributing to more robust scientific findings and more efficient translation of discoveries.

How does EGFR (Ab-869) Antibody compare with therapeutic anti-EGFR antibodies used in clinical applications?

While EGFR (Ab-869) Antibody is designed for research applications, understanding its differences from therapeutic antibodies provides important context for translational research:

Therapeutic anti-EGFR antibodies face challenges including:

• Off-target effects due to EGFR expression in normal tissues (which has led to development of pH-dependent antibodies that selectively bind in the acidic tumor microenvironment)

• Development of resistance through multiple mechanisms including secondary EGFR mutations, overexpression of bypass RTKs, and changes in the tumor microenvironment

• Limited efficacy as monotherapy, leading to exploration of combination approaches (e.g., antibody + TKI combinations)

Understanding these differences is crucial when using EGFR (Ab-869) Antibody in preclinical research aimed at developing or improving EGFR-targeted therapies.